Aldosterone blocker – Spironolactone has anti-inflammatory, anti-proliferative and anti-oxidative effects, that is why pathogenetically it is expedient to use it in complex therapy of rheumatoid arthritis.Material and methods: 46 patients with RA took 25-50 mg/day of Spironolactone during 12 months as an addition to standard therapy, the comparison group consisted of 47 patients that got only standard therapy, all the patients were fully examined prior and post the treatment.Results: complex RA therapy leads to improved VAS, HAQ, the antioxidative potential index F; decreased blood concentrations of TNF-α, ICAM-1, FGF and VEGF in contrast to standard therapy. Complex therapy made reduced the DAS 28 more > 0.6.Conclusions: applying of Spironolactone in complex therapy of rheumatoid arthritis contributes to more pronounced improvement in indices of articular syndrome and patient’s life quality, reduce of anti-inflammatory, anti-proliferative and angiogenic cytokines, and more effectively reduces the activity of the disease comparing to standard therapy.
BackgroundPatients with rheumatoid arthritis (RA) with subclinical hypothyroid dysfunction (SHTD) have early mortality due to cardiovascular complications. There for it is necessary to study this problem. Investigation of the SHTD effect on RA in these patients will help to define the prognosis and optimize the efficiency of integrated diagnostic and therapeutic tactics.ObjectivesTo determine the cardiovascular risk (CVR) level in RA patients with SHTDMethods98 patients with RA were examined. All the patients were divided into 2 groups. Group I – 59 (60,2%) patients with RA and SHTD, the second – 39 (39.8%) patients with RA without SHTD. Thyroid gland condition was determined according to international standards of SHTD diagnosis. All subjects were female. Patients in group I and II have not differed by age and RA duration. All patients underwent clinical and functional investigation for RA diagnosis. Blood levels of total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol cholesterol (LDL-C), very low density lipoproteins (VLDL) and atherogenic index (AI) were assessed. All patients underwent ultrasound detection of vascular endothelial dysfunction. CVR is calculated by Score scale. The results were multiplied by 1,5 factor according to the latest European guidelines for CVR in RA patients. The CVR level was also evaluated by Procam scale.ResultsCVR factors were significantly higher in the group I, than in group II (respectively 91.7%, 69.6%). Family history of cardiovascular disease was observed in 48.1% of patients I and 35.1% II group, higher BMI – respectively at 88.8% and 27.02% (p<0.001), dyslipidemia – at 79.6% and 43.2% (p<0.001), increased blood pressure – at 62.9% and 37.8% (p=0,003), menopause – at 57.4% and 24.3% (p<0.001). The total risk of cardiovascular death by Score scale in group I patients was 5.7%, in II – 3.2%, and by Procam scale in I – 18.5%, in II – 13.7%, it is significantly different (p<0.001).Parameters of lipid profile in group I compared with group II showed a significant increase of all investigated indices p<0.001, except for level of HDL cholesterol. In the study of endothelial function in both groups of patients the decrease of endothelium-dependent vasodilation (EDVD) and endothelium-independent vasodilation (EIVD) from standard indicators (EDVD brachial artery is (BA) greater or equal to 10%, and EIVD BA is more than 15%) was found. The average thickness of the complex intima-media (CIM) in patients of group I was 1.11±0.058 mm, and the II – 0.71±0.072 mm (p=0.009), which got statistical significance. Correlations between CIM and total cholesterol levels (r=0.297, p=0.021), LDL cholesterol (r=0.36, p=0.005), AI (r=0.335, p=0.008) in group I patients; and correlations between CIM and the level of LDL cholesterol (r=0.301, p=0.18) and AI (r=0.268, p=0.024) in patients of group II were defined.ConclusionsThe results show more significant changes of lipid profile and endothelial function indices in RA patients with concomitant SHTD, i...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.